

ROYALTY PHARMA

Royalty Pharma announces that Alexander von Perfall Joins Management Team

FOR IMMEDIATE RELEASE

New York, NY, December 7, 2009 -- Royalty Pharma is pleased to announce that Alexander von Perfall has joined the company as Vice President, Investor Relations.

Alexander has 13 years of cross-border management advisory, strategic planning and principal investment experience, most recently as co-founder and Chief Network Officer of XTF, a start-up Exchange Traded Funds Ratings Agency. He previously advised the International Finance Corporation/World Bank Group on the syndication of media sector private equity investments. Alexander started his career with Bertelsmann AG where he held various management positions, culminating with a position as Director of Business Development where he initiated and oversaw investments in a number of early stage media and entertainment ventures. Alexander attended the Hochschule St. Gallen in Switzerland before obtaining a BA in Politics from the University of San Francisco and an MBA from the New York University - Stern School of Business.

“The addition of Alexander to our management team adds an important element of investor relationship management,” said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. “Alexander will play a key role in Royalty Pharma’s efforts to enhance its investor and key stakeholder strategy and communication, including acting as a liaison between Royalty Pharma’s management team and equity and debt investors, the analyst community and media representatives.”

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with approximately \$6 billion in assets. Royalty Pharma currently owns a diversified portfolio of royalty interests in several high-quality blockbuster biopharmaceutical products, including Abbott’s Humira®, J&J/Merck’s Remicade®, Pfizer’s Lyrica®, Amgen’s Neupogen® and Neulasta®, Genentech’s Rituxan®, Gilead’s Emtriva®, Truvada® and Atripla®, and Celgene’s Thalomid®. Royalty Pharma has a thirteen year history of providing value to holders of royalty interests, including its \$700 million purchase of the Lyrica® royalty from Northwestern University, its \$650 million purchase of the Remicade® royalty from New York University, its \$700 million purchase of the Humira® royalty from AstraZeneca plc following its acquisition of Cambridge Antibody Technology, its joint \$525 million acquisition with Gilead Sciences of Emory University’s emtricitabine royalty interest and its acquisitions of approximately 80% of Memorial Sloan Kettering’s U.S. and international royalty interests in Neupogen® and Neulasta® for over \$400 million. For more information, go to www.royaltypharma.com

For additional information, please contact:

Pablo Legorreta
Chief Executive Officer
+ 1 (212) 883-2288
plegorreta@royaltypharma.com

Alexander v. Perfall
VP, Investor Relations
+ 1 (212) 883-2298
aperfall@royaltypharma.com

More information on Royalty Pharma is available at www.royaltypharma.com